NCT07136077 2026-02-27
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
4 trialsNCT05965479 2024-11-12
DECIPHER
University of Southampton
Phase 2 Recruiting
NCT06498752 2024-08-06
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06253650 2024-06-13
TRINITY
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting